Clarivate Plc has revealed that agentic AI functions have been extended beyond just Cortellis R&D workflow. They are embedding intelligent automation into current life sciences workflows to help in faster drug discovery, better safety assessments, and smarter portfolio strategies. These additions affect several modules: Cortellis Drug Discovery Intelligence: natural language query and fast target screening OFF-X: multi-agent intelligence-based proactive risk detection Cortellis Competitive Intelligence: faster and more market-efficient insight generation The suite moves beyond just providing information to actually doing work through embedded intelligence. The combination of human-curated data with AI is designed to assist pharma and biotech teams work more efficiently and to have accurate and fast insights from complex datasets.
Also Read: GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Lab Validation
Contextualizing this paradigm shift, Anne Lecocq, Senior Vice President and General Manager, R&D, Life Sciences & Healthcare, Clarivate, said: “In modern R&D, success depends on how quickly teams can translate complex data into decisive action. Cortellis is advancing this shift with agentic AI, evolving from insight delivery to workflow execution across the product lifecycle. Together, these innovations reflect the evolution of Cortellis from a trusted information source into a connected ecosystem of agentic capabilities that augment human expertise across the R&D lifecycle. Built on trusted data, it empowers teams to reduce friction, align decisions and act with precision in high-stakes environments.” Ultimately, this strategic rollout equips global research organizations to make faster, evidence-based decisions, optimize resource allocation, and accelerate the commercialization of impactful therapeutics.